ZEB1-high in patients with BRAFV600E CRC associated with metastatic resection (47% vs. 5%) and a better ECOG performance status (ECOG PS >2) (0% vs. 19%) relative to patients with BRAFV600E CRC in the ZEB1-low cohort (Figure 7, C and D). This evidence concerns the gene ZEB1 and colorectal carcinoma.